U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951021) titled 'Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab and Tuvonralimab, and SBRT in Hepatocellular Carcinoma With Macrovascular Tumor Thrombus' on Sept. 12.

Brief Summary: Hepatocellular carcinoma (HCC) with macrovascular tumor thrombus carries a poor prognosis, and systemic therapy alone provides limited benefit in this population. This single-center, single-arm, phase 2 trial evaluates the efficacy and safety of a regimen combining chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE), low-dose lenvatinib, the anti-PD-1/CTLA-4 bispe...